Deutsche Bank AG Sells 377,813 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Deutsche Bank AG lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 65.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,395 shares of the biopharmaceutical company's stock after selling 377,813 shares during the quarter. Deutsche Bank AG owned about 0.17% of Catalyst Pharmaceuticals worth $4,182,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Summit Investment Advisors Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 580 shares during the period. Bank of Montreal Can lifted its stake in shares of Catalyst Pharmaceuticals by 6.2% during the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after acquiring an additional 875 shares during the period. Rhumbline Advisers lifted its stake in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after acquiring an additional 952 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after acquiring an additional 1,000 shares during the period. Finally, PDT Partners LLC lifted its stake in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock valued at $431,000 after acquiring an additional 1,030 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.38 during mid-day trading on Friday, hitting $24.49. The company had a trading volume of 772,723 shares, compared to its average volume of 1,106,163. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The business's fifty day moving average is $23.53 and its two-hundred day moving average is $22.55. The firm has a market cap of $2.99 billion, a P/E ratio of 20.75, a P/E/G ratio of 3.31 and a beta of 0.70.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CPRX shares. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $32.29.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at $1,630,912.64. This represents a 74.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.